Fluoro-9-methyl-beta-carbolines Inner Ear Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inner ear diseases and hearing impairments, such as tinnitus and age-related hearing loss, face challenges in effectively targeting the inner ear due to the natural barriers of the biologic membranes, leading to limited efficacy and potential side effects.
Innovation Solution
The development of fluoro-9-methyl-β-carbolines, specifically 6-fluoro-9-methyl-β-carboline and 7-fluoro-9-methyl-β-carboline, which exhibit increased lipophilicity and membrane permeability, allowing for enhanced delivery to the inner ear and reduced toxicity, thereby improving therapeutic outcomes with lower doses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for inner ear diseases, then the treatment can be administered, but the biologic membranes block effective delivery to the inner ear, leading to limited efficacy
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of β-carboline compounds to introduce fluorine atoms at specific positions (6-fluoro and/or 7-fluoro substitutions). This structural modification changes the physical-chemical parameters of the compound, specifically increasing lipophilicity and altering membrane permeability characteristics, enabling the compound to overcome the biologic membrane barrier and reach the inner ear effectively
Solution Approach 2:
The invention creates a composite molecular structure by combining the β-carboline core framework with fluorine substituents. This composite structure integrates the neuroprotective properties of β-carbolines with the enhanced membrane permeability characteristics of fluorinated compounds, achieving both effective delivery through membranes and therapeutic action in the inner ear
2Reliability
If higher doses of conventional compounds are administered to overcome membrane barriers, then delivery to inner ear may improve, but toxicity and side effects increase
Solution Approach 1:
The fluorine substitution parameter change increases the lipophilicity parameter of the compound, which directly improves membrane permeability and delivery efficiency. This allows therapeutic concentrations to be achieved at lower administered doses, thereby reducing toxicity and side effects while maintaining effective delivery to the inner ear
3Reliability
If standard β-carbolines are used, then neuroprotective effect is provided, but metabolic degradation limits bioavailability and chronic treatment efficacy
Solution Approach 1:
The introduction of fluorine atoms at positions 6 and/or 7 of the β-carboline structure changes the metabolic stability parameter. The carbon-fluorine bond is highly stable and resistant to metabolic degradation, thereby extending the duration of action and improving bioavailability for chronic treatment while maintaining the neuroprotective effect
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds demonstrate increased efficacy in treating inner ear diseases by promoting neuronal differentiation, improving membrane permeability, and reducing metabolic degradation, leading to improved bioavailability and minimized side effects, particularly beneficial for chronic conditions.
Implementation Method 1
exhibit increased lipophilicity and membrane permeability
Implementation Method 2
improving membrane permeability
Implementation Method 3
promoting neuronal differentiation
Implementation Method 4
reducing metabolic degradation, leading to improved bioavailability
Data Source
AI summary
The present invention relates to fluoro-9-methyl-β-carbolines, their preparation as well as their medical use and pharmaceutical compositions containing fluoro-9-methyl-β-carbolines.